Clinical Trial

Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

Name: Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN — clinical trial record (NCT07390123)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN

Protocol Amendment History 1 change

notable Trial sites expanded: 1 -> 9 locations 2026-05-29

Trial Details

NCT Number	NCT07390123
Lead Sponsor	Haisco Pharmaceutical Group Co., Ltd.
Conditions	IgA Nephropathy (IgAN)
Enrollment	370 participants
Start Date	2026-04-07
Primary Completion	2027-12 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2026-05-28